Kelley Discusses Efficacy and Safety Considerations With the

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

Related Keywords

Durvalumab Imfinzi , R Katie Kelley , Ashling Wahner , Twitter , Linkedin , Department Of Medicine Hematology Oncology , Astrazeneca , Cancer Immunotherapy Program , Facebook , Single Tremelimumab Actl , Regular Interval Durvalumab , Apple Podcasts , Google Podcasts , Amazon Music , D , University Of California San Francisco Helen Diller Family Comprehensive Cancer Center ,